Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute bioavailability study of oral imatinib using an intravenous stable isotope microdose
NL-OMON46280Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imatinib in cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Absolute bioavailability of imatinib at steady state. Started Mar 2019; status: active, not recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON46280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46280.